Integra Lifesciences (IART) Trading 6.7% Higher

Integra Lifesciences Holdings Corp (NASDAQ:IART) traded up 6.7% during trading on Tuesday . The stock traded as high as $51.04 and last traded at $49.68. 1,782,600 shares changed hands during mid-day trading, an increase of 141% from the average session volume of 740,020 shares. The stock had previously closed at $46.55.

Several equities research analysts recently commented on the company. Bank of America downgraded Integra Lifesciences from a “buy” rating to a “neutral” rating in a report on Tuesday, January 2nd. BidaskClub downgraded Integra Lifesciences from a “sell” rating to a “strong sell” rating in a report on Friday, January 5th. UBS Group downgraded Integra Lifesciences to a “market perform” rating in a report on Tuesday, January 2nd. Cantor Fitzgerald reiterated a “neutral” rating and issued a $52.00 price objective on shares of Integra Lifesciences in a report on Friday, January 5th. Finally, Raymond James Financial restated a “market perform” rating and set a $55.00 price target on shares of Integra Lifesciences in a research note on Tuesday, January 2nd. One equities research analyst has rated the stock with a sell rating, ten have assigned a hold rating and three have issued a buy rating to the stock. Integra Lifesciences currently has a consensus rating of “Hold” and a consensus price target of $52.70.

The stock has a market capitalization of $3,860.00, a P/E ratio of 80.61, a PEG ratio of 1.55 and a beta of 0.65. The company has a current ratio of 4.49, a quick ratio of 3.39 and a debt-to-equity ratio of 1.26.

Integra Lifesciences (NASDAQ:IART) last released its quarterly earnings results on Thursday, October 26th. The life sciences company reported $0.45 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.47 by ($0.02). The firm had revenue of $278.83 million for the quarter, compared to the consensus estimate of $286.00 million. Integra Lifesciences had a net margin of 4.52% and a return on equity of 16.35%. The company’s revenue for the quarter was up 11.4% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.93 earnings per share. equities analysts predict that Integra Lifesciences Holdings Corp will post 1.85 earnings per share for the current fiscal year.

In related news, Director Barbara B. Hill acquired 10,768 shares of the stock in a transaction dated Tuesday, October 31st. The shares were purchased at an average cost of $46.66 per share, with a total value of $502,434.88. Following the transaction, the director now directly owns 55,540 shares in the company, valued at $2,591,496.40. The acquisition was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, VP Richard D. Gorelick sold 1,500 shares of Integra Lifesciences stock in a transaction dated Tuesday, November 14th. The shares were sold at an average price of $47.19, for a total value of $70,785.00. Following the transaction, the vice president now directly owns 21,665 shares in the company, valued at $1,022,371.35. The disclosure for this sale can be found here. Insiders own 21.50% of the company’s stock.

Several hedge funds have recently bought and sold shares of IART. Acrospire Investment Management LLC lifted its position in shares of Integra Lifesciences by 280.0% during the 2nd quarter. Acrospire Investment Management LLC now owns 1,900 shares of the life sciences company’s stock valued at $104,000 after buying an additional 1,400 shares in the last quarter. Riverhead Capital Management LLC lifted its position in shares of Integra Lifesciences by 49.9% during the 2nd quarter. Riverhead Capital Management LLC now owns 2,399 shares of the life sciences company’s stock valued at $131,000 after buying an additional 799 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in shares of Integra Lifesciences by 8.6% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,752 shares of the life sciences company’s stock valued at $150,000 after buying an additional 218 shares in the last quarter. Whittier Trust Co. purchased a new position in shares of Integra Lifesciences during the 3rd quarter valued at about $169,000. Finally, San Francisco Sentry Investment Group CA purchased a new position in shares of Integra Lifesciences during the 2nd quarter valued at about $174,000. 87.58% of the stock is currently owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION NOTICE: “Integra Lifesciences (IART) Trading 6.7% Higher” was originally published by Community Financial News and is the property of of Community Financial News. If you are viewing this news story on another site, it was illegally copied and republished in violation of US & international copyright and trademark laws. The original version of this news story can be viewed at https://www.com-unik.info/2018/01/11/integra-lifesciences-iart-trading-6-7-higher.html.

Integra Lifesciences Company Profile

Integra LifeSciences Holdings Corporation is a medical technology company. The Company focuses on the development, manufacturing, and marketing of surgical implants and medical instruments. Its segments include Specialty Surgical Solutions, which offers specialty surgical instrumentation for a range of specialties, including product portfolio used in the neurosurgery operating suite and critical care unit, and Orthopedics and Tissue Technologies, which includes differentiated soft tissue repair and tissue regeneration products, and small bone fixation and joint replacement solutions.

Receive News & Ratings for Integra Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit